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(747 words)  
Accounting for about 15% of all strokes, with one-month mortality around 40% 1, 
spontaneous, nontraumatic acute intracerebral haemorrhage (ICH) causes a substantial 
global disease burden. Although stroke unit care2 and acute blood pressure lowering 
improve outcome3, there is an urgent need for more effective acute treatments. Craniotomy 
and surgical evacuation aims to reduce or remove the haematoma, thus reducing mass 
effect and direct or secondary tissue injury, yet has not shown benefit in large pragmatic 
randomized controlled trials4. Less invasive strategies aim to achieve haematoma removal 
or reduction, with less associated brain tissue injury, and show promising outcomes in 
small studies5.  
 
The minimally invasive surgery plus recombinant tissue plasminogen activator in 
intracerebral haemorrhage evacuation (MISTIE) trial assessed whether minimally invasive 
surgery (MIS) and rt-PA is safe and reduces clot burden, and obtained preliminary 
functional outcome data. All patients were managed in high-level care, with an intervention 
of a small craniotomy, image-guided catheter aspiration, thrombolysis with rt-PA, 
irrigation and drainage over several days. An initial rt-PA dose-finding stage led to stage 
two of the trial, in which 96 patients with spontaneous ICH ≥20 ml, “clinically stable” after 
6 hours (clot expansion <5ml and no active bleeding on CT) were randomized to standard 
medical guideline-based care or MIS and rt-PA thrombolysis plus guideline-based care. 
The primary outcome was “good outcome” on the adjusted dichotomized modified Rankin 
Scale (mRS) (0-3 vs 4-6) at 180 days. Primary safety outcomes were mortality, 
symptomatic bleeding, brain infections, and withdrawal of care. The population included 
67% men, average age 61 years, with 66% basal ganglia and 34% lobar haematoma 
locations. The mean entry ICH size was 46ml, and median Glasgow Coma Scale 10. Safety 
outcomes did not differ between groups. At 180 days, the proportions with good recovery 
(mRS 0-3) were 33% in the MIS and rt-PA arm and 21% in the comparator medical arm. 
After adjustment for important potential imbalances in baseline severity (NIHSS, GCS, 
ICH volume and IVH volume) the absolute difference in the proportion achieving a 
favourable outcome was 0.162 [95%CI: 0.003, 0.323; p=0.05]. Asymptomatic and 
symptomatic bleeding were both more common in the MIS group (22% vs. 7%, p= 0.05; 
and 9.3% vs. 2.4%, p=0.226, respectively). 
 
How should clinicians interpret these results? The headlines are that MIS and rt-PA does 
not increase mortality, has an apparent advantage of better functional outcome at 180 days 
(albeit only marginally statistically significant), but causes increased bleeding (both 
asymptomatic and symptomatic). Nevertheless the trial provides important new 
randomized evidence that a standardized minimally invasive neurosurgical intervention 
might improve outcome after ICH. The method is theoretically attractive in minimizing 
cortical trauma and excision, and in reducing clot volume to reduce both mechanical and 
secondary inflammatory or toxic injury. However, some aspects merit careful 
consideration. First, of 4103 patients screened, only 96 (less than 3%) were randomized, 
suggesting generalizability only to a minority of patients with ICH, although participants 
with deep and lobar ICH were included. Second, the intervention is complex, requiring 
adherence to a lengthy study intervention protocol with varied success measures in the trial, 
and most likely even greater variation if translated to real-world practice. Third, although 
apparently not increasing mortality, the study confirms that using rt-PA increases the risk 
of bleeding, albeit not at the expense of net long-term functional benefit - analogous to the 
accepted early ICH risk and improved long-term functional outcome associated with rt-PA 
in acute ischaemic stroke6. Finally, this small trial was not powered to show efficacy, 
leading to a wide range of estimated treatment effects.  
 
It remains uncertain to what extent the apparent benefit of MIS is due to direct clot volume 
reduction through aspiration (limiting mass effect), or the use of rt-PA to continue 
removing blood products from the hematoma cavity (potentially reducing inflammation 
and other toxic secondary injury). Other techniques including clot endoscopic aspiration 
under direct guidance (without rt-PA) might therefore be of interest7. Although exploratory 
analyses suggest that better clot removal is associated with improved outcome, proving this 
hypothesis requires further trials.  Thus, although MISTIE is a promising step forward, 
much larger trials in ICH patients recruited from both stroke and neurosurgical units are 
essential, to ensure that the results are not due to chance and can be replicated in current 
practice; until then the data are unlikely to directly influence current neurosurgical 
approaches. Nevertheless, if MISTIE and other minimally invasive techniques can be 
proven to produce meaningful functional benefit in patients with ICH, this could herald a 
new era in treating this most devastating of neurological emergencies.  
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